Deallus

We're delighted that, as part of our 20th anniversary celebrations, we can showcase some of our alumni who, over that period, have all played a part in our journey so far. We are very proud of all our Deallus team - past, present and future.   We conclude our 2024 Alumni celebrations with Philip Miller who was with Deallus for seven years starting as Research Consultant and progressing to Head of EMEA & LATAM.   Philip says of his time: “One of the best memories at Deallus was the Las Vegas retreat. It was not only a great party(!) but a celebration of how far the company had come. I joined as the 8th employee after being interviewed in a ‘rent-by-the hour’ office. In just a few years, we expanded to 100 people and were working with almost all leading pharma companies. It was amazing to be part of that and to see the impact of our work.   What I learned at Deallus still serves me well today. My PhD gave me appreciation for depth of expertise but soon after joining the company, I realised my main interest and value as a consultant was associated more with breadth. Diversity of clients, engagement types, therapy areas, technologies and geographies provided me with the grounding to be able to make connections across topics and to contribute my thinking towards identifying the right questions and, most importantly, arriving at robust choices.”   #alumni #insights #breadthanddepth #informing #projectwork #development #growth #diversity #connections

We're delighted that, as part of our 20th anniversary celebrations, we can showcase some of our alumni who, over the past 20 years, have all played a part in our journey so far. We are very proud of all our Deallus team - past, present and future. We are delighted to profile Chester Wong who was with Deallus for four years as Director and Business Unit Manager. Chester says of his time: “One of the most valuable insights I learned during my time at Deallus was the importance of understanding different players at the table, what drives them and how they may react to different situations. While not a crystal ball, it has helped me make better decisions and respond more quickly to changes.  I was also lucky enough to have the opportunity to attend several international conferences. I always made sure to make the most of seeing so many new places and this experience has really instilled my love of travel.” #alumni #insights #decisionmaking #conferences #understandingpeople 

We were delighted to welcome Suffwan Eltom back to Deallus as part of our alumni programme. Suffwan was with Deallus for seven years and is now Chief of Staff, BioPharmaceuticals Business Unit at AstraZeneca.   The Q&A session, hosted by our Chief Commercial Officer Julie Munch Khan, was a fascinating insight into Suffwan’s career journey so far, the choices he’s made, and how to make the most of opportunities and challenges. An inspiring and engaging presenter, everyone who attended, from recent graduates to more seasoned experts, learnt a lot. It was wonderful to welcome Suffwan back to the Deallus family.   At Deallus we are so proud of all our team - past, present and future. The alumni programme is part of our 20th anniversary celebrations and an opportunity for us to showcase and celebrate those who have played a part in our journey so far.   #alumni #20yearscelebrations #insightful #learnings #opportunities #thankyou #celebrate

Deallus is proud to have contributed to the advancement of healthcare within Duchenne Muscular Dystrophy (DMD), a severely debilitating disease. Deallus recently provided commercial due diligence support to R-Bridge, an affiliate of CBC Group, in their royalty financing transaction with Santhera. In the transaction, up to USD 38 million of royalties in Santhera’s AGAMREE (vamorolone), a novel corticosteroid for DMD patients, will be monetized. https://lnkd.in/evH423hY   This transaction will help fund the advancement of AGAMREE’s access to patients and support Santhera’s further developmental initiatives.   The Deallus team was led by Kevin Bibby, Senior Principal, and the engagement managed by Kate Richardson, PhD, Manager. We wish every success to the R-Bridge team in this transaction.   Deallus is a leading global strategy consultancy in the healthcare space, whose services include commercial due diligence and support for pharma Business Development & Licensing teams. You can find out more here: https://lnkd.in/e-qqpGRq #advancinghealthcare #DMD #duediligence #commercialexpertise #consulting #improvingpatientlives

At Deallus we are so proud of all our team - past, present and future. As part of our 20th anniversary celebrations we wanted to showcase some of our alumni who, over the past 20 years, have played a part in our journey so far.   We are delighted to profile Andy Walton who was with Deallus for six years as Financial Controller, and subsequently Head of Finance.   Andy says: “I learnt a huge amount during my time at Deallus. Attention to detail remains core to what is important and looking at things from different viewpoints: the more ways you look at a problem, the better you can solve it. Also, the importance of relationship building and how it’s the key to working collaboratively.   One of my favourite memories from working at Deallus was the Florence retreat. The location alone made the trip a memorable one, but what sticks out in my memory was the great blend of learning and relaxation with colleagues. Ulrike Meier (Deallus Chairwoman of the Board) was a fantastic coach and her ability to both challenge and bring the best out of people is a great skill. Learning to make pasta (properly) was also a real highlight!”   #alumni #collaboration #problemsolving #relationshipbuilding #finance #retreat #coaching #learning

As part of Migraine Awareness Week in the UK, Deallus Chief Commercial Officer Julie Munch Khan has authored the first in a short series of blogs: The Migraine unveiling: Bringing the invisible disability to light. You can read the blog here: https://lnkd.in/eKsnevwJ   With insights and collaboration from Rob Music, Chief Executive of The Migraine Trust, and Dr Victoria Wallace, Consultant Neurologist, the paper explores the impact of migraine for those living with the condition, the complexities of diagnosis and treatment, and the work still needed to improve awareness of the impact of migraine. Deallus is committed to working with our clients, as well as providers and those supporting patients, to ensure progress continues to be made. Read the blog here: https://lnkd.in/eKsnevwJ #migraineawarenessweek #migraine #neurology #improvingpatientslives #impact #insights #blog

Deallus is proud to be supporting Migraine Awareness Week in the UK. A neurological condition, 1 in 7 people live with migraine, making it the second most prevalent cause of disability worldwide. With women three times more likely to be diagnosed vs men, migraine is the leading cause of disability in women aged 15–49 years. Migraine impacts every aspect of life of those diagnosed - from physical to mental health, quality of life, and relationships. Yet in many ways it remains a hidden disability.   Deallus is committed to working with our clients, as well as providers and those supporting patients, to ensure insights and progress continues to be made.   Over the coming weeks, we will be delivering a series of insights on migraine, with support and collaboration from The Migraine Trust as well as Victoria Wallace. Please get in touch if you would like to receive these directly: https://lnkd.in/ehBub766 #migraineawarenessweek #migraine #neurology #improvingpatientslives #impact #insights #series #blogs

Our AI powered Deallus Landscape Analyser maximises the impact of consulting and scientific team’s time by allowing them to focus on creating value and supporting clients’ strategic decision making rather than manually building a therapeutic area/competitor landscape from scratch. The Deallus Landscape Analyser is live, continuously updating and therefore creating impactful therapeutic area and competitor landscapes almost instantaneously. It draws information from trusted sources and brings significant efficiency in work and knowledge updates. It reduces timelines and resource requirements in various projects and activities. As well as creating landscapes, the tool provides information for our clients in strategic meetings for TA explorations, aids in clinical trial design activities, trial pipeline assessments. This landscape has wide range applications for various teams in asset development and journey such as: - Competitive intelligence - Market Access - BD&L - Medical Affairs - Brand Planning - R&D - Clinical trial planning You can find out more here: https://lnkd.in/eSbhjtqD Or get in touch for a demo: [email protected] #AI #impact #value #insight #realtimeinformation #therapyarea #landscape #efficiency #dealluslandscapeanalyser

Please join us at Pharma CI USA where Deallus Senior Principal Anna Scott, Ph.D. will be presenting on Wednesday 25th September at 16.10. Anna’s session, entitled: CI for Nontraditional Client Archetypes, will look at how CI partners with stakeholders throughout the drug development and commercialization life-cycle. If you are currently working for or in a CI or insights function, come build your toolkit with practical tips and tricks for navigating the variety of partnerships between CI and functional teams. Anna will be joined at the conference by Deallus Principal Dario Ceric. If you would like to find out more, or to meet with Anna or Dario, please get in touch here: https://lnkd.in/e6TPpFug You can also find out more about the Pharma CI USA Conference here: https://lnkd.in/eweeYrHT #pharmaciusa #conference #competitiveintelligence #presenting #strategy #lifesciences

What are the key building blocks of a value-based market access and reimbursement strategy? How do payers approach formulary decisions as a function of clinical outcomes? And how do country-to-country interactions influence individual country value price setting? At Deallus we’re excited for our Head of US, and Vice President, Peter Barschdorff (包培德), to chair the 8th Pharma Pricing, Reimbursement, and Market Access conference, organised by our friends at Virtue Insight, and set to kick off on September 19th in Philadelphia (PA). Peter started his pharma consulting career more than twenty years ago heavily focused in market access. He went on to lead engagements including public and commercial access, pricing, and reimbursement for medical devices, pharmaceuticals, and vaccines. Later, in big pharma executive roles, he oversaw, i.a. market access insights and analytics. For several years now, he’s built the Deallus US team and shepherded market access capabilities.               Do get in touch if you would like to meet up at the conference. #conference #VIppr #insights #marketaccess #pricing #analytics #reimbursement #pharma